BIG trials to be highlighted at ASCO 2017

Intro text: 

The annual ASCO meeting will be taking place from 2 to 6 June 2017 and will gather over 30,000 oncology professionals from all corners of the world. 

This year, the BIG network is happy to be presenting several studies taking place under its umbrella. 

  • The phase III APHINITY study, which is part of ASCO’s official press programme on Monday 5 June, will be presenting detailed results. This trial is testing whether adding a drug called pertuzumab to the standard adjuvant treatment (trastuzumab and chemotherapy) in patients with operable HER2-positive primary breast cancer improves the outcome of patients with the disease.

    An initial announcement was made in March 2017, which stated that Roche’s Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy.
    (Abstract LBA500)
  • On Sunday 4 June, Dr Fatima Cardoso will be presenting a poster on Standard anthracycline-based vs. docetaxel-capecitabine in early breast cancer : Results from the chemotherapy randomisation (R-C) of the MINDACT phase III trial
    (Poster Board #116) (Abstract 516)
  • The phase III ALTTO trial,  a randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer, will have updated results presented at an oral abstract session on Monday 5 June
    (Abstract 502)
  • Dr Jens Bodo Huober will be presenting, on Sunday 4 June, a poster with updated results of survival outcomes for NeoALTTO, the Neo-Adjuvant Lapatinib and/or Trastuzumab Treatment Organisation study is a randomised, multicentre open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer.
    (Board 112) (Abstract 512)